Some new information about the anti-inflammatory actions of GIP from @RolaHammoud1 Gain and loss of GIPR signaling modifies gut inflammation in mice with 5FU-induced enteritis, with data on Tirzepatide & Semaglutide @JCI_insight @BBDC_UofT @SinaiHealth @CIHR_IRSC

A brain-gut-heart GLP-1-pericyte pathway mediating remote ischaemic cardioprotection

The DACRAs are advancing through clinical development #weightloss #obesity Here mechanistic interrogation of cagrilintide action in mice

Revisiting NPY2R #obesity Studies in mice reveal synergistic activity of NPY2R and GCGR/GLP-1R agonism via survodutide is an attractive anti-obesity target #weightloss .@MolMetab

Dozens of studies illustrate the feasibility of engineering probiotics to secrete GLP-1 and Rx #diabetes in mice.

Roles for VAMP-8 in GLP-1R recycling in beta cells

Among the ways for next generation GLP-1 medicines to differentiate: Efficacy, safety and outcome trials in type 1 #Diabetes

The authors propose that targeting adipocyte CLDN5 could have potential therapeutic implications for metabolic diseases @NatureComms

A graded effect of maternal hyperglycaemia on offspring’s metabolic risk #diabetes @DiabetologiaJnl

Where do islet beta cells come from and how to regenerate? The answers depend on how one utilizes distinct neogenesis and proliferative pathways @NatureComms #diabetes

A retrospective propensity-matched cohort analysis from TriNetX reveals lower rates of cardiovascular events in users of GLP-1 medicines with #T2D with Monoclonal Gammopathy of Undetermined Significance

Innovation in the #weightloss space continues with an emerging Triple G oral peptide #obesity to enter into clinical development for obesity in 2026.

Studies in mice reveal that LEAP2 analogs have the potential to enhance the efficacy of glucagon-like peptide 1 receptor agonism and support durable #weightloss

Here transkingdom multi-omic microbial shifts as potential contributors to iMASLD aetiopathogenesis. @NatMetabolism .

Retrospective claims data reveals over 20 % of GLP-1 medicine users had nutritional deficiencies diagnosed within one-year of starting GLP-1RA treatment.

More retrospective data highlighting that Glucagon-like peptide-1 receptor agonist use increased the odds of inadequate bowel preparation and repeat procedure.

An extensive resource ( for the further exploration of the mouse adipocyte epigenome which will enable discovery of regulatory elements governing adipocyte identity and gene regulation

Journals are overwhelmed by meta-analyses and Mendelian randomization submissions. How to evaluate the keyboard warrior generated Tsunami while preserving fairness and quality @DiabetologiaJnl

Looking for innovations in next generation GLP-1 medicines? #obesity Don’t overlook China

#Exercise continues to be the best medicine. A personalized exercise therapy and self-management support program is more effective than usual care alone in improving health-related quality of life at 12 months in adults with multimorbidity @naturemedicine

#Exercise continues to be the best medicine. A personalized exercise therapy and self-management support program is more effective than usual care alone in improving health-related quality of life at 12 months in adults with multimorbidity @NatureMedicine